Overview of Efficort

The identity of the medicinal product known as Efficort is defined by its core substance and its established pharmacological classification for the relief of skin inflammation.

Property	Description
Active Ingredient	Hydrocortisone
Form	Topical Cream (Dermatological Preparation)
Pharmacological Class	Glucocorticoid (Corticosteroid)
Common Use	Relief of Inflammatory Skin Conditions
Origin	Synthetic (Derived from Cortisol)

What Type of Medicine is Efficort and How is it Classified?

Efficort is classified as a dermatological preparation intended for topical application, belonging to the pharmacological class of corticosteroids, more specifically glucocorticoids. The drug is derived from the core structure of Hydrocortisone, chemically positioning it as a synthetic compound that mimics the anti-inflammatory effects of the body's naturally produced hormone, Cortisol. This classification signifies that Efficort is designed to function as a potent localized anti-inflammatory agent and a local immunosuppressant in the skin tissue. It is recognized for its efficacy in mitigating localized inflammatory processes.

Composition and Form: The Role of Hydrocortisone

The product's identity is defined by its single product formulation, where the active ingredient is Hydrocortisone (INN). Efficort is supplied as a topical cream, which is an emulsified base engineered for direct dermal application. Hydrocortisone is a commonly utilized anti-inflammatory agent recognized for its ability to reduce inflammation when applied locally. The choice of a cream dosage form is distinct from heavier formulations like ointments; the cream is generally preferred for its ease of absorption into various weeping or moist inflammatory skin conditions.

What is the General Purpose of Efficort Cream?

The general purpose of Efficort cream is to provide relief from the core symptoms of inflamed, irritated, or allergic skin states. As a glucocorticoid, its main function is to stabilize the skin’s condition by reducing the associated redness, swelling, and itching (pruritus relief). These agents exert a vasoconstrictive effect, which helps to reduce localized swelling. The medication achieves this by inhibiting the local biological processes that lead to inflammation, thereby addressing the tissue's exaggerated response to irritation.

Regulatory References

What side effects are possible with Efficort?

Possible Side Effects and Safety Information for Efficort (Hydrocortisone Butyrate)

Efficort is a potent topical corticosteroid, and its safety profile is defined by local cutaneous reactions and the potential for systemic absorption, particularly with misuse.

Common Adverse Reactions

The most frequently reported side effects are localized to the application site, reflecting the drug's topical nature. These include:

Skin reactions: Burning, itching, irritation, redness, and dryness.
Dermatological changes: Folliculitis (inflammation of hair follicles), hypertrichosis (excessive hair growth), acneiform eruptions, and signs of skin atrophy, such as thinning or striae (stretch marks).
Other: Hypopigmentation (lightening of the skin) and secondary infections due to skin barrier changes.

Clinically Significant Safety Concerns

While systemic absorption is generally low, it can lead to clinically significant effects, especially with prolonged use, application to large surface areas, or under occlusive dressings. The primary concern is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a systemic effect common to all potent corticosteroids. This risk is higher in the pediatric population due to a greater ratio of skin surface area to body weight.

Safety Restrictions and Limitations

Regulatory documents emphasize specific restrictions for use:

Contraindications: Use is generally avoided in the presence of skin tuberculosis, fungal infections, or viral infections (e.g., herpes) at the treatment site, as corticosteroids can worsen these conditions.
Avoidance Areas: The drug should not be used on the face, axillae (armpits), or groin unless strictly directed by a healthcare provider, and application in these areas should be limited in duration.
Occlusion: The use of occlusive dressings or bandages significantly enhances drug absorption and is strongly discouraged unless explicitly advised by a physician.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Efficort (topical hydrocortisone) outlines overdose as a risk primarily associated with systemic absorption following prolonged, excessive use, application to large areas, or use under occlusive dressings.

Documented Manifestations

This systemic absorption of the corticosteroid into the bloodstream can lead to clinical signs resembling Cushing's syndrome, hyperglycemia, and the presence of sugar in the urine (glucosuria). The most serious documented consequence of chronic excessive use is reversible hypothalamic-pituitary-adrenal (HPA) axis suppression. Should HPA suppression be confirmed through mandated tests, such as the ACTH stimulation test or the urinary free cortisol test, regulatory guidance recommends reducing the frequency of application or discontinuing the product. Steroid withdrawal symptoms may occur upon cessation, which may require supplemental systemic corticosteroids.

When to Seek Urgent Medical Help

Urgent medical help must be sought immediately if the cream is accidentally ingested (swallowed), requiring contact with a Poison Control Center. For management of overdose, treatment is generally supportive and symptomatic, as no specific antidote is known. Furthermore, children are documented as being more susceptible to systemic toxicity, which may manifest in specific ways, including linear growth retardation.

Therapeutic Uses of Efficort

Quick Facts

Primary Use: Management of inflammatory and pruritic manifestations of corticosteroid-responsive skin conditions.
Therapeutic Areas: Supports care for conditions such as eczema, atopic dermatitis, and psoriasis.
Main Benefit: Provides relief from symptoms including redness, swelling, and itching in affected skin areas.

Efficort is indicated for the relief of inflammatory and pruritic (itchy) manifestations associated with dermatological conditions that respond to topical corticosteroids. This medication may be used to help manage symptoms stemming from conditions like eczema, atopic dermatitis, and psoriasis.

The therapeutic application of the medication is focused on addressing localized symptoms. It works to ease discomfort and reduce the visible signs of skin irritation, such as redness and swelling, which are common features of these conditions. Using Efficort may help patients maintain well-being by providing relief from persistent itching and inflammation.

Treatment with this medication should always be initiated under the guidance of a healthcare professional.

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Efficort?

Eligibility to use Efficort (topical Hydrocortisone) is defined by official regulatory documentation, focusing on contraindications and specific population restrictions.

Populations and Conditions to Avoid

Category	Regulatory Status
Absolute Contraindication	Patients with known hypersensitivity to hydrocortisone or any component of the cream must not use it.
Infection/Skin Conditions	The cream is contraindicated for use on active, untreated bacterial, viral (e.g., herpes), fungal, or parasitic infections of the skin. Use is also restricted for rosacea, acne vulgaris, and perioral dermatitis.

Restricted or Conditional Use

Category	Official Restriction
Age Groups	Children and infants (especially those under two years) have restricted use; prolonged treatment is generally discouraged due to the risk of systemic absorption.
Pregnancy/Lactation	Use during pregnancy is restricted to situations where the benefit outweighs the potential risk. Nursing mothers should use caution and avoid application to the breast area.
Application Site	Application to the face, eyes, eyelids, or ano-genital areas is generally restricted or contraindicated. Use under occlusive dressings is also restricted.

Eligibility criteria are strictly governed by these official labeled rules, establishing who is permitted to use the medicine and who is prohibited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Efficort (Topical Hydrocortisone) based on the conditional risk of systemic absorption, as direct drug-drug interactions are not known under standard use. The risk becomes relevant only if the medication is absorbed significantly into the bloodstream, which is not the intended primary action.

Documented Interaction Patterns

The primary conditional interaction involves agents that affect systemic drug clearance. Co-administration with potent CYP3A4 inhibitors may potentially decrease the clearance of any systemically absorbed hydrocortisone, thereby increasing the risk of systemic exposure and related effects, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This is an official pharmacokinetic interaction concern tied to the drug’s metabolism.

Restrictions and Additive Exposure

Pharmacodynamic Interaction: The concurrent use of other corticosteroid-containing products (either topical or systemic) carries a documented risk of additive exposure. This results in a cumulative systemic steroid level and is officially cautioned against.

Procedural Constraints: The potential for systemic interaction is formally increased by application conditions such as use over large surface areas, application for prolonged periods, or use under occlusive dressings. These conditions augment percutaneous absorption and activate the systemic interaction risk.

Population Note: Pediatric patients are officially recognized to be at a greater risk for systemic toxicity and potential interaction relevance due to their high skin surface-to-body-mass ratio.

Mechanism of Action

Efficort works by engaging the intracellular Glucocorticoid Receptor ( GR) as an agonist, a primary molecular action that initiates its complex cascade of effects. This binding leads to the translocation of the drug-receptor complex into the cell nucleus, where it acts as a gene modulator. The mechanism involves both Transactivation (increasing expression of anti-inflammatory genes like Annexin A1) and Transrepression (suppressing pro-inflammatory transcription factors like NF-kappa B). This genomic control modulates the cell's output by suppressing pro-inflammatory gene expression and promoting the synthesis of anti-inflammatory proteins.

The genomic action directly results in the disruption of the central Arachidonic Acid Cascade, a central pathway in the synthesis of inflammatory mediators. The synthesis of Annexin A1 indirectly leads to the inhibition of the enzyme Phospholipase A2 ( PLA2), preventing the formation of prostaglandins and leukotrienes. By suppressing these mediators and reducing the synthesis of cytokines like TNF-alpha, the mechanism results in reduced synthesis of multiple pro-inflammatory mediators.

The final stage of the mechanism involves the physiological consequences at the tissue level: local vasoconstriction and immunosuppression. The drug reduces the overall local blood flow and permeability of the capillaries in the skin. Simultaneously, it dampens the function and migration of immune cells, such as T-lymphocytes and macrophages, into the affected area. These actions lead to the observable physiological effect of reduced tissue swelling, which results in a local physiological reduction in tissue reaction.

Dosage and Administration Information

How to Use Efficort: Official Administration Guidelines

Efficort, a topical preparation containing Hydrocortisone, is administered solely via the cutaneous route (applied to the skin surface) and is strictly for external use only.

Standard Dosing and Frequency

The standard approach involves applying a thin film or a small quantity of the cream to the affected area. The dosing frequency varies based on local prescribing information. Regimens include application two to four times daily, or once or twice daily. The frequency may be reduced (e.g., to once or twice a week) as part of a step-down regimen.

Course Duration and Procedural Constraints

The continuous use of the cream is generally intended to be short-term, typically limited to a maximum of seven days without medical review. The treated skin area must not be covered with bandages, plasters, or any occlusive dressings unless specifically instructed by a healthcare professional, as this can alter systemic absorption. The cream should be gently rubbed in until it disappears, and application should avoid the eyes, face, and broken or infected skin.

Population-Specific Rules

Administration guidelines for children are more restrictive. Use in children under 12 is typically not recommended without supervision, and treatment courses for infants and children should generally be limited to no more than seven to ten days. For infants treated in the diaper area, tight-fitting diapers or plastic pants must not be used, as they act as occlusive coverings.

Recent Clinical Evidence

Research evidence / Overview of studies for Efficort

Evidence for Use in Atopic Dermatitis (Eczema)

Research has explored this medicine in studies concerning conditions characterized by fluctuating or episodic manifestations, such as eczema. The evidence base includes many Randomized Controlled Trials (RCTs) and Systematic Reviews that have explored this medicine in studies to assess symptoms and recurrence. Research has explored these studies during periods of increased symptom activity to evaluate changes measured during the study period.

Researchers specifically monitored outcomes related to physical discomfort, using tools like disease severity scoring systems (e.g., SCORAD and EASI), and they examined how specific symptoms like itching (pruritus) and redness were measured in the observed populations.

Despite the substantial volume of research over time, the body of evidence contains a number of older trials where evidence quality varies across studies, which may complicate the comparability of results. Furthermore, while research has explored short-term symptom changes, there is limited information for long-term outcomes regarding consistent use or the durability of the observed findings over extended periods.

Research for Psoriasis and Other Inflammatory Dermatoses

Research has also explored this medicine in studies concerning psoriasis, a condition marked by functional limitations and periods of heightened symptoms. This evidence often comes from Comparative Trials where the medicine was studied against other common topical agents, as well as from Regulatory Bibliographical Applications that refer to the long history of research in this area.

Studies explored outcomes related to physical discomfort by monitoring clinical signs, such as changes in scaling and plaque thickness, with findings describing patterns observed during the study period.

For the general category of corticosteroid-responsive dermatoses, the evidence primarily contributes to the broader evidence landscape by describing patterns related to its activity in this context. For these general uses, regulatory conclusions often refer to the long history of research in this area.

Evidence in Special and Vulnerable Populations

The existing evidence base has monitored different patient groups. Specifically, studies monitored populations encompassing both adults and children (pediatric cohorts) with conditions like eczema. The research was often applied in studies examining patient-reported experiences in patients classified with mild to moderate disease severity levels.

While research describes patterns related to symptom changes in these varied groups, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes related to consistent use in all specific pediatric age groups. Findings reported in the trials generally reflect the specific conditions under which they were conducted, and research describes group patterns and does not determine whether an individual will experience similar outcomes.

Research Gaps and Uncertainty

The main research gaps stem from the fact that many of the original trials for this class of medicine were conducted a significant time ago, meaning the evidence quality varies across studies and some were of modest methodological rigor compared to modern standards.

Furthermore, there is a recognized lack of high-quality comparative evidence across certain subgroups, and data for certain groups remain insufficient. Because follow-up durations were modest in many primary efficacy trials, there is limited information for long-term outcomes regarding the effects of consistent or repeated use. Therefore, while research helps contextualize how patients reported their experience during the study period, certainty remains low regarding outcomes outside of the tightly controlled, short-term trial settings.

Frequently Asked Questions (FAQ)

Common questions about Efficort (FAQ)

Q: Is Efficort the same as other steroid creams I've used?

Official drug classifications place Efficort's active ingredient, Hydrocortisone Butyrate, in the category of moderately potent topical corticosteroids. This classification defines its strength relative to other steroid creams, which may range from low to high potency. Understanding its strength relative to other topical corticosteroids requires consulting the product label and guidance from a healthcare professional.

Q: Is it normal to feel a mild stinging when first using Efficort?

Official product information for this class of medicine often reports local adverse reactions, including burning and irritation, at the application site. While mild stinging may be part of this initial feeling of irritation, any persistent or severe reaction is generally advised to be reported to a healthcare provider for evaluation.

Q: Does Efficort have any systemic absorption into the bloodstream?

Yes, systemic absorption, meaning the medicine enters the bloodstream, can occur with topical corticosteroids like Efficort. While the amount absorbed is typically low, factors like prolonged use, application over large areas, or use under an occlusive dressing can increase the amount absorbed. Regulatory documents state that use should be in accordance with official labeling to minimize this risk.

Q: Are there any studies comparing the safety profile of Efficort to similar drugs?

The body of research evidence for this class of medicine includes comparative trials which assess the medicine against other topical agents. These studies primarily evaluate effectiveness but also include monitoring for adverse events. However, regulatory documents often note that the quality and comparability of safety data may vary across these older trials.

Q: Can Efficort affect blood sugar levels, especially for people with diabetes?

Due to the potential for systemic absorption, the use of topical corticosteroids may rarely lead to systemic side effects like hyperglycemia (high blood sugar). The potential for systemic effects may necessitate clinical monitoring, which is particularly relevant for patients with pre-existing conditions such as diabetes.

Q: What happens if I accidentally swallow a small amount of Efficort?

Efficort is strictly for external use only and is not intended for oral ingestion. Official regulatory labels indicate that if the medication is accidentally swallowed, seeking immediate medical help or contacting a Poison Control Center is advised.

Q: Is Efficort available over the counter in any countries?

The regulatory status of hydrocortisone-based products varies internationally. Lower-strength topical hydrocortisone is frequently available over-the-counter (OTC) in many jurisdictions for minor skin issues. However, the specific Efficort formulation may still require a prescription, depending on the country’s regulations.

Q: Is Efficort a high, medium, or low potency steroid?

The active ingredient in Efficort, Hydrocortisone Butyrate, is generally classified by regulatory bodies as a moderately potent topical corticosteroid. The potency level guides its appropriate use and duration of treatment for various skin conditions.

Q: Why is Efficort sometimes prescribed for insect bites?

Efficort's classification as an anti-inflammatory and anti-itch agent makes it useful for relieving symptoms of various inflammatory dermatoses. Although Efficort may be a prescription product, over-the-counter hydrocortisone products are commonly labeled for temporary relief of itching and inflammation associated with minor irritations, including insect bites.

Q: How long should I wait to see if Efficort is helping my condition?

Official product labeling advises that if a patient does not observe any improvement in their condition within two weeks of starting treatment, they should consult a healthcare provider. Regulatory labeling advises a reassessment of the diagnosis may be warranted if no improvement is noted within that timeframe.

Q: What are the main risks associated with stopping Efficort suddenly?

Upon discontinuing use, especially following prolonged or widespread application that resulted in systemic absorption, some patients may experience signs and symptoms of topical steroid withdrawal. Official guidance notes that this may sometimes require treatment with supplemental systemic corticosteroids.

Q: Does Efficort contain any parabens or common allergens?

While the specific composition of every formulation may vary, some regulatory labels for hydrocortisone products (including the cream dosage form) list common excipients such as methylparaben and propylparaben as ingredients. For patients with known allergies, reviewing the full list of inactive ingredients is a critical informational step.

Q: What is the active ingredient's concentration in Efficort cream?

Approved formulations of Hydrocortisone Butyrate cream, which is the active ingredient in Efficort, are commonly available in a concentration of 0.1% (or 1 mg/g). The concentration level is a key factor in the drug's overall potency classification.

Q: Are there generic versions of Efficort available?

The active ingredient, Hydrocortisone Butyrate, is widely used, and official regulatory databases list multiple manufacturers producing the ingredient under generic formulations (ANDA-approved products). These generic versions contain the same active ingredient and strength as the brand-name product.

Q: Are there known interactions between Efficort and common skincare products?

Patient guidance for this type of medication describes limitations on the concurrent use of cosmetics or other skin care products on treated areas without direction from a healthcare provider. This precaution is intended to help minimize unknown interactions or changes in drug absorption.

Q: What if I forget to apply Efficort one time?

Patient guidance for this type of medication advises that if a dose is missed, it should be applied as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. Official guidance advises against doubling the application to compensate for a missed dose.

Q: Does Efficort have potential for drug abuse or dependence?

Official safety profiles and regulatory fact boxes for Hydrocortisone Butyrate indicate that this medication is not classified as habit-forming and is not a controlled substance. Therefore, it does not carry a formal risk of drug abuse or dependence.

Q: Are there specific instructions for washing hands after applying Efficort?

Yes, official patient guidance advises that users should wash their hands thoroughly with soap and water both before and after applying this medicine. This practice is necessary to prevent accidental transfer of the medication to sensitive areas, such as the eyes.

How should Efficort be stored and disposed of?

How to Store and Dispose of Efficort

The storage of Efficort (Hydrocortisone Cream) is defined by strict regulatory requirements intended to maintain product stability and potency. The cream must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is mandatory to protect the product from freezing.

Container and Protection

The medicine should be kept in the container it came in, and the cap must be kept tightly closed to protect it from light and excess moisture. For safety, Efficort must always be stored out of the reach of children.

Disposal Requirements

Any unused or expired medicine should not be kept. Disposal must be conducted by asking a healthcare professional or pharmacist for guidance and following all applicable local, regional, and national regulations. Utilizing an approved community drug take-back program is the official best option for discarding the medicine.

Efficort